drugset / Trial / NCT06737354
Safety and Efficacy Study of IVB103 Injection in Subjects With Neovascular (Wet) Agerelated Macular Degeneration (nAMD).
Phase 1
Enrolling by invitation
18 enrolled
InnoVec Biotherapeutics Inc.
NeoVec Biotherapeutics Inc. · collab
Non-randomizedSequentialOpen-labelTreatment
Summary
The goal of this clinical trial is to evaluate the safety and efficacy of IVB103 injection in subjects with nAMD.
Timeline
- Start
- 2025-04-22
- Primary completion
- 2027-12-31
- Completion
- 2031-12-31
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | IVB103 | Unknown | — | Intravitreal |